Oxana Beskrovnaya Sells 2,334 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the transaction, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Oxana Beskrovnaya also recently made the following trade(s):

• On Wednesday, September 18th, Oxana Beskrovnaya sold 2,339 shares of Dyne Therapeutics stock. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $25.61 on Friday. The company has a 50 day moving average price of $30.53 and a two-hundred day moving average price of $35.24. Dyne Therapeutics, Inc. has a 52 week low of $10.80 and a 52 week high of $47.45. The company has a market capitalization of $2.61 billion, a PE ratio of -7.19 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its position in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares in the last quarter. Quantbot Technologies LP acquired a new position in Dyne Therapeutics during the third quarter worth $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the third quarter worth $36,000. US Bancorp DE boosted its holdings in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new position in Dyne Therapeutics during the third quarter worth $62,000. Institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on DYN. Chardan Capital restated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price objective on the stock. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Finally, Oppenheimer restated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $50.82.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.